Translational oncology - 26/05/2020 Translation: driver of cancer medicine The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field. https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
Material research - 25/05/2020 Reaching up into weightlessness – a start-up that enables commercial research experiments in space Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
Trenzyme GmbH - 20/05/2020 The SARS-CoV spike protein and its receptor The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
Press release - 19/05/2020 Cyber Valley welcomes five new members to its Start-Up Network Five new companies from the Stuttgart/Tübingen region in southwestern Germany have joined the Cyber Valley Start-Up Network. The innovative technologies and products of AmbiGate, Cytolytics, Mojin Robotics, plus10 and Tactai aim to achieve ground-breaking improvements in the fields of public health, manufacturing, and customer service. These start-ups join ten other companies that are already part of the Cyber Valley Start-Up Network.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-begruesst-fuenf-neue-mitglieder-seinem-start-network
Press release - 14/05/2020 CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
Press release - 13/05/2020 Corona antibody tests from Reutlingen The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
Press release - 13/05/2020 Drug counterfeiters use fear of corona epidemic Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie
Press release - 12/05/2020 CeGaT Offers Corona Antibody Test Since May 11, 2020, CeGaT offers a CE certified corona antibody test. This test determines whether a person has antibodies against the coronavirus SARS-CoV-2. People who have antibodies are assumed to have undergone a coronavirus infection and are highly likely to be immune.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-bietet-corona-antikoerpertest
Press release - 07/05/2020 Privacy-aware Corona Tracing App Identification of contacts is one of the most important measures to mitigate the spread of the Corona virus. Tracing apps are to help. Technical implementation, however, is associated with the risk of data misuse and the approaches presented so far do not sufficiently protect privacy. Researchers of Karlsruhe Institute of Technology (KIT) and of the FZI Research Center for Information Technology have now proposed an app that enhances privacy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/datenschutzfreundliche-corona-tracing-app
Heidelberg Technology Park - 05/05/2020 Start-up support for life sciences companies How can scientists turn their know-how into marketable products and services and thereby provide society with real added value? In addition to solid financing, start-up companies need a suitable infrastructure and a dense network of partners for exchanging expertise to help them get off to a good start when it comes to setting up a business. The Heidelberg Technology Park offers company founders in the life sciences exactly these success factors.https://www.gesundheitsindustrie-bw.de/en/article/news/start-up-support-for-life-sciences-companies
Press release - 04/05/2020 CorTec is again Germany’s Most Innovative Company For the third time in a row CorTec is ranked among the most innovative companies in Germany. Statista has been conducting out the survey since 2014 and has joined forces with German business magazine Capital for the first time this year for the award. Together with 14 other companies in the medical devices industry, CorTec is entitled to carry the title “Germany’s Most Innovative Company” in this segment.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CorTec-is-again-Germany-s-Most-Innovative-Company
Press release - 27/04/2020 EIT Health pledges €6m funding to accelerate COVID-19 solutions EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020 A rapid pyrogen test: the human immune system as model Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.https://www.gesundheitsindustrie-bw.de/en/article/news/A-rapid-pyrogen-test-the-human-immune-system-as-model
Press release - 22/04/2020 Rapid help for hospitals Medical safety eyewear, disinfectant dispensers and ventilators from 3D printers – experts from the Fraunhofer Institute for Manufacturing Engineering and Automation IPA are using their technological expertise in the fight against the coronavirus pandemic. https://www.gesundheitsindustrie-bw.de/en/article/press-release/schnelle-hilfe-fuer-kliniken
Press release - 17/04/2020 CoroNotes: New app supports medical studies on COVID-19 Scientists from the Tübingen Competence Center for Machine Learning and physicians from the University Hospital of Tübingen have developed an app that uses anonymous health data to contribute to a better understanding of the novel coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/coronotes-neue-app-unterstuetzt-medizinische-studien-zu-covid-19
Prime Vector Technologies GmbH - 09/04/2020 A modular brick system for developing a COVID-19 vaccine Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
Press release - 08/04/2020 New Alliance in the Fight Against Coronavirus and COVID-19 Scientists from Heidelberg and Mannheim launch research and development task forcehttps://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
Press release - 08/04/2020 “Access checker” remotely measures body temperature in addition to heart and breathing rate An innovative measurement method is helping to detect people infected with coronavirus from a safe distance. It detects fever, increased pulse rates and fast breathing without endangering the person conducting the testing. Fraunhofer IPA and Fraunhofer IAO are currently testing the procedure at the Robert Bosch Hospital in Stuttgart.https://www.gesundheitsindustrie-bw.de/en/article/press-release/access-checker-misst-koerpertemperatur-herz-und-atemfrequenz-aus-der-ferne
Bioinspired technologies - 03/04/2020 Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests? The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.https://www.gesundheitsindustrie-bw.de/en/article/news/Diagnostics-with-molecular-scissors-is-this-also-possible-for-on-site-COVID-19-tests
Press release - 24/03/2020 State aid: Commission approves €300 million Luxembourg scheme to support companies affected by coronavirus outbreak The European Commission has found Luxembourg's €300 million scheme to support companies affected by the coronavirus outbreak to be in line with EU State aid rules. The scheme was approved under the State aid Temporary Framework to support the economy in the context of the COVID-19 outbreak adopted by the Commission on 19 March 2020.https://www.gesundheitsindustrie-bw.de/en/article/press-release/state-aid-commission-approves-eur300-million-luxembourg-scheme-support-companies-affected-coronavirus-outbreak
Press release - 23/03/2020 COVID-19: Commission launches European team of scientific experts to strengthen EU coordination and medical response Today, the European Commission launched an advisory panel on COVID-19 composed of epidemiologists and virologists from different Member States to formulate EU guidelines on science-based and coordinated risk management measures.https://www.gesundheitsindustrie-bw.de/en/article/press-release/covid-19-kommission-setzt-europaeisches-team-wissenschaftlicher-experten-ein-um-die-koordinierung-auf-eu-ebene-und-die-medizinis
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps://www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Save-the-date - 15/06/2023 - 17/06/2023 REHAB 2023 Karlsruhe, Messe https://www.gesundheitsindustrie-bw.de/en/event/rehab-2023
Press release - 16/03/2020 CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide
Multiple sclerosis - 12/03/2020 Direct application of biopharmaceuticals through the nose into the brain There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain